Healthcare Industry News: Agensys
News Release - September 30, 2008
Seattle Genetics Adds to Senior Management TeamBOTHELL, Wash.--(HSMN NewsFeed)--Seattle Genetics, Inc. (Nasdaq: SGEN ) today announced the appointments of Elaine Waller, PharmD to Senior Vice President, Regulatory Affairs and Christopher Pawlowicz to Senior Vice President, Human Resources, as well as the promotion of Jonathan Drachman, M.D. to Vice President, Early Clinical Development.
“A strong senior management team is essential to the successful execution of our aggressive corporate goals, including moving SGN-35 into pivotal trials planned for 2009,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Jonathan’s promotion reflects his dedication and the substantial drug development acumen he has demonstrated in his four years with the company. Our team is further strengthened by the additions of Elaine and Chris who have extensive experience in their respective fields. We look forward to leveraging Elaine’s background in collaborating with the FDA and Chris’s experience in organizational and leadership development as Seattle Genetics continues to advance and grow.”
Elaine Waller, PharmD, has more than 20 years of experience in regulatory affairs and clinical research. Prior to joining Seattle Genetics, Dr. Waller was with Sonus Pharmaceuticals, where she served as Senior Vice President, Regulatory Affairs/Quality Assurance and Clinical Research until its merger with OncoGenex Pharmaceuticals in August 2008. Before that, she was Chief Operating Officer at Radiant Research, a clinical site management organization. Dr. Waller’s previous experience includes senior positions in regulatory affairs and clinical research at Hoechst Marion Roussel and Marion Merrell Dow. She began her career in academia at the University of Texas at Austin where she held teaching positions in both graduate and undergraduate pharmacy education and was Assistant Director of Clinical Research at the Drug Dynamics Institute. Dr. Waller received a B.S. in Pharmacy and a Doctor of Pharmacy from the University of Missouri – Kansas City and an M.B.A. from Rockhurst College.
Christopher Pawlowicz joins Seattle Genetics with more than 25 years of human resources experience, principally from positions in the pharmaceutical industry. Prior to Seattle Genetics, Mr. Pawlowicz was Senior Vice President, Human Resources and Administration at MedPointe Pharmaceuticals, a specialty pharmaceutical company. Before that, he worked as Corporate Vice President, Human Resources at Express Scripts Incorporated, the nation’s third largest pharmacy benefit management company. Mr. Pawlowicz’s career has also included senior human resources positions at Pharmacia, Searle Pharmaceutical Company and Monsanto Company. He received his B.A. in Economics from Benedictine College in Atchison, Kansas and his M.A., Labor and Industrial Relations degree from the University of Illinois - Urbana-Champaign, Illinois.
Jonathan Drachman, M.D. has been with Seattle Genetics since 2004, serving most recently as Senior Medical Director. Since joining the company, Dr. Drachman has led clinical development strategy and execution for multiple programs, including SGN-40. As Vice President, Early Clinical Development, he oversees the activities involved in transitioning Seattle Genetics’ antibody-based therapeutics from preclinical into clinical development. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine and fellowship in Medical Oncology at the University of Washington in Seattle.
About Seattle Genetics
Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company has four product candidates in ongoing clinical trials: SGN-40, SGN-33, SGN-35 and SGN-70. SGN-40 is being developed under a worldwide collaboration with Genentech. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics, Daiichi Sankyo and MedImmune, a subsidiary of AstraZeneca, as well as an ADC co-development agreement with Agensys, a subsidiary of Astellas Pharma. More information can be found at www.seattlegenetics.com.
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the company’s plan to advance SGN-35 into pivotal trials and expectations of continued advancement and growth. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates move into and advance in clinical trials. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Seattle Genetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.